Low-molecular-weight heparins in the treatment of acute coronary syndromes

Archives of Internal Medicine

Volumn 161, Issue 12, 2001, Pages 1484-1490

  Turpie, Alexander G G ^a   Antman, Elliott M ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG BIOAVAILABILITY; DRUG EFFICACY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; META ANALYSIS; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA;

EID: 0034917336     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.12.1484     Document Type: Review

References (50)

1. Plaque fissuring: The cause of acute myocardial infarction, sudden ischemic death, and crescendo angina
2. The pathogenesis of coronary artery disease and the acute coronary syndromes
3. Tissue-factor antigen and activity in human coronary atherosclerotic plaques
4. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques
5. Activation of blood coagulation by plaque rupture: Mechanisms and prevention
6. Low molecular weight heparins: An intriguing new twist with profound implications
7. Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death: Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion
8. Angiographic stenosis progression and coronary events in patients with "stabilized" unstable angina
9. Angiographic and clinical progression in unstable angina
10. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI III B trial
11. Low-molecular-weight heparin during instability in coronary artery disease
12. Incidence and follow-up of Braunwald subgroups in unstable angina pectoris
13. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
14. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina
15. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: Long-term effects on the risk for myocardial infarction, occurrence of severe angina, and the need for revascularization
16. Aspirin, sulfin-pyrazone, or both in unstable angina: Results of a Canadian multicenter trial
17. Aspirin, heparin or both to treat acute unstable angina
18. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
19. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina
20. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: A meta-analysis
21. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
22. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction
23. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina
24. Reactivation of unstable angina after the discontinuation of heparin
25. Heparin-induced thrombocytopenia
26. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes
27. Are the available low-molecular-weight heparin preparations the same?
28. Low molecular weight heparins: Are they different?
29. Low-molecular-weight heparins: Pharmacologic profile and product differentiation
30. The tissue factor pathway of coagulation
31. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin
32. Chemical and biological heterogeneity in low molecular weight heparins: Implications for clinical use and standardization
33. Low molecular weight heparin(s)
34. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
35. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAXIS
36. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
37. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC)
38. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease
39. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial
40. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE Study: Efficacy and safety of subcutaneous enoxaparin in non-Q wave coronary events
41. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B/ESSENCE meta-analysis
42. Treatment benefit of enoxaparin in unstable angina/ non-Q-wave myocardial infarction is maintained at one year followup in TIMI 11B
43. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis
44. Economic assessment of low molecular weight heparin (enoxaparin) versus UFH in acute coronary syndrome patients: Results from the ESSENCE randomized trial
45. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation
46. Prior aspirin use predicts worse outcomes in patients with non-ST elevation acute coronary syndromes
47. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A
48. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins
49. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: Beneficial effects of enoxaparin
50. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina